Effects of a new immunotherapeutic agent (CG5601) on endotoxin-induced uveitis.

Abstract

CG5601 is a novel immunomodulatory substance showing anti-inflammatory properties comparable to thalidomide. To investigate the anti-inflammatory effects of CG5601 in endotoxin-induced uveitis (EIU) and to evaluate its influence on leukocyte-endothelium interaction, the anterior chamber inflammatory reaction was assessed and intravital fluorescence microscopy was carried out at 2, 4, 8 and 24 h. Lewis rats received an intraperitoneal injection of CG5601 (200 mg/kg b.w.) at the time of lipopolysaccharide injection. At 8 and 24 h, CG5601 inhibited the cell migration and protein concentration in the aqueous humor compared to untreated EIU (p < 0.0001). There was no significant difference between nontreated animals and vehicle controls. The treatment of CG5601 reduced the number of rolling leukocytes. At early time points (2 and 4 h), inhibition of rolling leukocyte flux was significant (p < 0.005). The rise of serum TNF-alpha levels in EIU at 2 h was reduced. CG5601 exerts potent anti-inflammatory effects in EIU.

• Authors: A U Porstmann, K Zwingenberger, U Pleyer, H Baatz
• Journal: Ophthalmic research (Ophthalmic Res) 2003 May-Jun Vol. 35 Issue 3 Pg. 143-9 ISSN: 0030-3747 [Print] Switzerland
• PMID: 12711841 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2003 S. Karger AG, Basel

Chemical References

• Anti-Inflammatory Agents
• CG5601
• Endotoxins
• Imidazoles
• Lipopolysaccharides
• Spiro Compounds
• Thiazoles
• Tumor Necrosis Factor-alpha
• Thalidomide

Topics

• Animals
• Anti-Inflammatory Agents (therapeutic use)
• Aqueous Humor (metabolism)
• Disease Models, Animal
• Drug Evaluation, Preclinical
• Endotoxins
• Female
• Imidazoles (therapeutic use)
• Leukocyte Rolling (drug effects)
• Leukocytes (drug effects)
• Lipopolysaccharides (toxicity)
• Rats
• Rats, Wistar
• Spiro Compounds (therapeutic use)
• Thalidomide (analogs & derivatives, therapeutic use)
• Thiazoles (therapeutic use)
• Time Factors
• Tumor Necrosis Factor-alpha (metabolism)
• Uveitis (chemically induced, drug therapy)